Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect
Abraham et al 1 report their experience with shortening the duration of post-transplant immunosuppression by rapid tapering of cyclosporin (CsA) between 30 and 60 days in adult patients at high risk of relapse of AML and with no evidence of acute GVHD. They concluded that an early taper of CsA can be used with reasonable safety in a high risk population undergoing allogeneic BMT. Our unit had adopted a similar policy in children for acute leukaemia. Between January 1993 and October 1997, 24 children underwent BMT for acute leukaemia from fully matched sibling donors and received CsA and MTX as GVHD prophylaxis. Age at BMT was 2.4-11.7 years (median 7.3); 14 were males and 10 females. The main groups were ALL (conditioned with TBI 1320cGy in 8 fractions over 4 days/CY, 120 mg/kg); 12 patients were in CR 2 , and five high risk patients in CR 1 . Seven patients with AML were conditioned with BU 600 mg/m 2 /CY 120 mg/kg; six were in CR 1 and one was in early relapse. GVHD prophylaxis consisted of MTX, 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, 6 and 11. All were treated according to a common CsA regimen, with 3 mg/kg i.v. from day −1 followed by oral treatment when tolerated. In the absence of GVHD by day +30, a rapid taper of CsA was commenced, with the aim of ceasing CsA by day +100. Treatment with CsA was continued and systemic steroids added for treatment of acute GVHD. There was one early transplant-related mortality. Of the remaining 23 patients, 12 had no evidence of acute GVHD and underwent CsA taper followed by early discontinuation at a median of 92 days post BMT (range 77-112 days). Eleven patients received steroids and continued CsA for GVHD (n = 9) or suspected GVHD (n = 2). However, in this group CsA was still discontinued by a median of day +226 (167-380). Of those who developed acute GVHD, eight had grades I and II, one had grade III and none developed grade IV. The two patients who developed chronic GVHD ceased CsA on days +256 and +380. No patient developed chronic GVHD after commencing the rapid taper of CsA. Of the 24 patients, 20 are alive and disease free, one is alive and in relapse, three died: one was the early transplant-related death mentioned above; there was a fatal second malignancy; one of the patients who had chronic skin GVHD had also developed RSV pneumonitis on day 0 of her transplant, and had multiple organ problems. This patient continued to have progressive restrictive respiratory symptoms after all signs of GVHD had abated and died of respiratory failure. At no time had GVHD been considered as part of her lung pathology. Duration of follow-up for the 21 survivors ranged from 0.46 to 5.03 years (median 2.15).
Relapse after allogeneic HLA-identical BMT for acute leukaemia is the major cause of therapeutic failure of this procedure. Graft-versus-leukaemia effect may help prevent the recurrence of haematological malignancy following allogeneic BMT. [1] [2] [3] Such an effect may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of CsA. 1 We do not know the required duration of immunosuppression for prevention of GVHD. A common approach to withdrawal of CsA is gradual dosage taper over 6 months to 1 year. Omission of any GVHD prophylaxis is associated with a high rate of GVHD, even in children. 4 Individualised prophylaxis against GVHD based on estimated risk of GVHD development vs disease recurrence is an important approach. 5 A report analysing 28 recipients of HLA-identical sibling marrow grafts showed that despite the frequent occurrence of low CsA trough levels, effective GVHD prevention was achieved. 6 In two sequential US studies in children with AML, augmentation of GVHD prophylaxis using 6 months of CsA in addition to short-course MTX improved transplant-related mortality from 31% to 11%, but this was counterbalanced by an increase in the relapse risk from 22% to 35%. 7 A recent randomized study in children with acute leukaemia compared CsA, 1 mg/kg/day vs 3 mg/kg/day. The lower dose was associated with more acute GVHD but less relapse. 8 Thus, in an attempt to minimise the development of severe GVHD but maximise the potential GVL effect, we have maintained a standard dose of CsA for the first month post BMT and then used a rapid CsA taper. This approach may explain the low incidence of relapse and satisfactory results overall in our patients.
